Veracity Capital LLC Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Veracity Capital LLC cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,266 shares of the medical research company’s stock after selling 51 shares during the period. Veracity Capital LLC’s holdings in IQVIA were worth $249,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter valued at $28,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.7 %

IQVIA stock opened at $204.54 on Friday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $37.12 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The stock has a 50-day moving average of $199.47 and a two-hundred day moving average of $221.09.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Bank of America decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. Finally, TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.